This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Active years: 2026.
Years Active: 2026
Title: Innovations by Johanna Michael in Leukotriene Receptor Antagonists
Introduction
Johanna Michael is an innovative inventor based in Salzburg, Austria. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of diseases associated with neuroinflammation. Her work focuses on improving the bioavailability of leukotriene receptor antagonists, which are crucial in managing various health conditions.
Latest Patents
Johanna Michael holds a patent for a method of treatment and device aimed at enhancing the bioavailability of leukotriene receptor antagonists. The patent, titled "Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists," describes an oral film dosage form designed to deliver these antagonists, such as Montelukast, effectively to the stomach. This innovative method involves an alkaline surface pH film that allows for the delivery of Montelukast in an amorphous precipitate suspended in an aqueous medium. The device is specifically formulated to achieve enteral delivery, ensuring that the medication can cross the blood-brain barrier, which is essential for treating neurodegenerative diseases.
Career Highlights
Johanna Michael's career is marked by her dedication to advancing medical treatments through innovative drug delivery systems. Her work at Nualtis Corp. has positioned her as a key player in the pharmaceutical industry, where she continues to explore new methods for improving drug efficacy and patient outcomes.
Collaborations
Johanna collaborates with talented professionals in her field, including Nadine Paiement and Rodolphe Obeid. These partnerships enhance her research and development efforts, contributing to the success of her innovative projects.
Conclusion
Johanna Michael's contributions to the field of pharmaceuticals, particularly through her patent on leukotriene receptor antagonists, demonstrate her commitment to improving healthcare solutions. Her innovative approach to drug delivery continues to pave the way for advancements in treating neuroinflammatory conditions.